Tereza Vanova

Sep 1, 2023 | biorxiv.org | Durga Jha |Tereza Vanova |Dasa Bohaciakova |Zdenek Spacil

AbstractBeta and gamma-secretase inhibitors have been of pharmacological interest to reduce abeta (Aβ) formation and aggregation, a defining characteristic of Alzheimer's disease (AD). Recent research indicates that Apolipoprotein E (ApoE), another genetic risk factor for AD, can regulate secretase activity. Secretase inhibitor-induced elevation of neuronal membrane lipids has been documented in 2D models.